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Polyclonal intravenous immunoglobulin
(IVIg) treatment reduces crossmatch positivity and
increases rates of transplantation in highly sensi-
tised patients (HS). We quantified the panel reac-
tive antibody (PRA) by microlymphocytotoxicity
(MLCC), and we analysed anti-HLA class I and
class II IgG specific antibody repertoire by Lu-
minex before and after IVIg infusion alone in HS
patients awaiting kidney transplantation. 
Five patients received three monthly infusions
of 1 g/kg of IVIg. Serum samples collected pre and
post IVIg treatment were submitted for PRA
analysis by MLCC. Anti-class I and anti-class II
antibody specificities were then tested by Lu-
minex. We focused on the anti-HLA class I and
class II antibodies directed against HLA expressed
by a previous graft. We also analysed the anti-HLA
antibody repertoire in three patients who had not
received IVIg infusion. The PRA level determined
by MLCC decreased significantly in one of the five
patients, dropping from 40% to 17%. The Lu-
minex assay showed fluctuations of the anti-HLA
antibody levels over time, but no significant long-
term modifications of the anti-HLA antibody
repertoire were observed, even in the patient with
a strong and prolonged reduction of the PRA de-
termined by MLCC. 
Our results show that IVIg at 1 g/kg is not suf-
ficient to reduce PRA and does not modify the
repertoire of specific anti-HLA antibody deter-
mined by Luminex.  
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The presence of antibodies against donor
HLA is associated with hyperacute or severe acute
rejection, often leading to graft loss [1, 2]. HLA
anti-donor antibodies are detected by a crossmatch
testing. If positive, the result is a contra-indication
for kidney transplantation. In Switzerland, 10% of
patients on a waiting list for a first kidney trans-
plant are immunised with anti-HLA antibodies.
This number rises to 55% for those waiting for a
re-transplantation [3]. Immunisation can occur
after blood transfusion [4], pregnancy [5] or any
organ transplantation [1, 2, 6]. Different ap-
proaches have been used to try to decrease HLA
antibodies in hyperimmunised patients. Desensi-
tisation with plasmapheresis or immunoabsorp-
tion may help remove anti-HLA antibodies but
these methods are associated with a rapid re-emer-
gence of anti-HLA antibodies [7–9]. Several teams
have successfully decreased anti-HLA antibody
levels in highly immunised (HS) patients awaiting
kidney or heart transplantation, using polyclonal
intravenous immunoglobulins (IVIg) [10–15]. The
efficacy of the therapy has been attributed to sev-
eral mechanisms including the presence of IgG
anti-idiotype antibodies, saturation of Fc receptors
on the macrophage surface, inhibition of comple-
ment-mediated injury, inhibition of inflammatory
cytokine production, inhibition of T and B lym-
phocyte proliferation, and antibody production
[16–24]. A dose of 2 g/kg of IVIg was used in 
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the most recent studies [12, 13, 25], but doses of 
0.4 g/kg or 0.1 g/kg in addition to plasmapheresis
have also been shown to reduce the PRA MLCC,
or to induce negative crossmatch [11, 25]. The
inhibitory effet of the IVIg on HLA-alloantibody
has been tested in vitro by several groups with con-
troversial results depending on the readout used 
in the study [14]. However, nothing is known on
the in vivo effect of IVIg given without additional
immunosupressive drugs on HLA-alloantibody
repertoire determined by high sensitive technol-
ogy recently developed.
In this study, using Luminex we analysed the
impact of IVIg given alone on the anti-HLA anti-
body repertoire in a group of patients who received
IVIg infusions at an intermediate dose of 1 g/kg. 
Material and method
Patients
The study included five HS patients with anti-HLA
alloantibodies (isotype IgG) due to a blood transfusion,
pregnancy or prior organ transplantation, and who had
been waiting for a cadaveric donor kidney transplantation
for at least one year. Only those patients with a PRA that
had remained stable (less than 20% fluctuation) for at least
one year were eligible for the study. Patients received at
least three monthly infusions of 1 g/kg of IVIg Redim-
mune® (ZLB Behring AG) in addition to their usual treat-
ment. None of them were transfused during the time of
the study and none of them were given immunosuppres-
sive drugs. Serum samples were analysed before, as well as
1 month and 6 months after the last IVIg infusion. Because
he was successfully desensitised, patient 4 received three
additional IVIg infusions and late time points were
analysed. Three additional HS patients who did not re-
ceive IVIg infusions but who had been on the waiting list
for several years were also analysed. Serum samples from
these patients were assessed over a period of at least six
months. None of them received blood transfusions during
the study. None of them were on immunosuppressive
drugs. The study was approved by the ethics committee of
the institution and all patients had signed an informed
consent.
Panel Reactive Antibody (PRA)
To quantify the panel-reactive antibody in study
patients, serum samples were tested in a microlymphocy-
totoxicity assay (MLCC) against an HLA-typed lympho-
cyte panel of 30 cells. Lymphocytes were isolated by Ficoll,
washed, and dispensedinto oiled Terasaki trays containing
1 μl of patient tested serum per well. Cells were incubated
with serumfor 30 min at 21°C and then with complement
for 3 h (PBL) or 2 h for T cells isolated on Dynabeads
(HLA Cell Prep 1; Dynal, Great Neck, NY) [26].  
Luminex technology
LABScreen® class I and class II uses a panel of HLA-
antigens coated on the surface of colour-coded micro-
spheres to determine percent PRA and to identify antibody
specificities. Serum samples were collected from the pa-
tients and stored at –20 oC until use. 5 ml of class I panel
(LS1PRA, LABScreen® PRA and LS1A01, LABScreen®
Single Antigen) or class II panel (LS2PRA, LABScreen®
PRA and LS2A01, LABScreen® Single Antigen) micro-
beads (Luminex Corporation, Austin, Tx) were added 
to 20 ml of serum, and the mix was incubated for 30 min
at room temperature and processed according to manu-
facture instructions (One Lambda, Inc) [27]. Anti-HLA
antibody detection and results interpretation were per-
formed using LABScan™ 100 software (One Lambda,
Inc.) on the Luminex® 100™ instrument (Luminex Corpo-
ration). Serum samples of each patient were analysed with
the same batch of LABScreen® Class I and II. The inten-
sity of anti-HLA antibody is scaled 2, 4, 6, or 8 by Lu-
minex. 2 is negative, 4 is intermediate, 6 and 8 are clearly
positive. 
Results
Study characteristics and adverse events
The characteristic of the five patients included
in the study, their diagnosis and the number of
transplantations before being included in the study
are described in table I. PRA values were those
recorded at the time of entry in the study. To com-
pare the effect of IVIg with the natural fluctuations
of anti-HLA antibodies, three additional stable pa-
tients were also extensively analysed. The charac-
teristics of the patients who did not receive IVIg
are also described in table 1. PRA values ranged
from 39 to 100% in patients treated and non-
treated before the beginning of the IVIg treatment
(table 1). The infusions were performed during 
an off-dialysis day. Infusion symptoms, including
headaches, were monitored during,at the end, and
1 h after infusion. Only one patient described mild
episodes of headaches during two infusions.
Therefore, in this study, infusion of IVIg at 1 g/kg
is considered to be safe.
Panel Reactive Antibody determined 
by microlymphocytotoxicity (PRA MLCC) 
before and after IVIg
PRA levels were first determined by MLCC at
specified intervals during the study period and one
month after the last IVIg infusion. Because the
PRA MLCC is not specific for anti-HLA antibody,
the serum samples of all patients were tested and
found positive with a specific anti-IgG HLA anti-
body Elisa assay. Lambda Antigen Trays (LAT™,
One Lambda Inc., Canoga Park, CA), which fea-
ture purified HLA Class I and Class II antigens
attached to a Terasaki-format tray, are designed 
for the detection of HLA IgG antibody (data not
shown). The fluctuations of the PRA MLCC in the
control group are shown in figure 1B.
Because patient 4’s PRA fell by more than 50%
the patient received three additional monthly IVIg
infusions (figure 1C, arrows), and the PRA MLCC
remained at low levels after the three additional in-
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Patienta Age Genderb Prior grafts Diagnosisc PRA % Nb of MMe
(years) by MLCCd (total)
P1 58 F 1 SLE 72% 2
P2 38 M 2 GN 39% 9
P3 59 M 1 GN 61% 2
P4 39 M 1 Reflux 45% 4
P5 62 F 3 SLE 50% 10
C6 43 F 2 IDD 100% 6
C7 69 F 1 GN 68% 3
C8 54 F 0 PKD 61% –
a P1 to P5 refer to patients 1 to 5, receiving IVIg treatment as described in Material and Method. 
C6 to C8 refer to control patients 6–8, not receiving IVIg.
b F, female; M, male
c SLE = systemic lupus erythematous (non active), GN = glomerulonephritis
IDD = insulin-dependent diabetes, PKD = polycystic kidney disease
d PRA, panel reactive antibodies detected by microlymphocytotoxicity (MLCC) on 30 cells
at the beginning of the study
e Nb of MM, number of mismatch A B DR between the patient and previous transplant(s)
Table 1
Clinical characteris-
tics of patients in-
cluded in the study.
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Figure 1
Changes in Panel
Reactive Antibody
determined by micro-
lymphocytotoxicity
(PRA MLCC) during
the study.
A Changes in PRA
levels before and
after three monthly
infusions of IVIg 
1 g/kg in sensitised
patients awaiting
kidney transplanta-
tion (P1 to P5)
B Changes in PRA
levels over a 
6-month period in
sensitised patient
awaiting kidney
transplantation, 
not receiving IVIg
(C6 to C8)
C Long-term changes
in PRA levels in
patient 4. Patient 4
received three
monthly infusions
of IVIg before de-
creasing his PRA,
and a further three
monthly IVIg infu-
sions. The IVIg
infusions are indi-
cated as arrows.
fusions. However, a slow but constant increase of
PRA MLCC was recorded in the weeks following
the last IVIg infusion, which showed that the re-
duction of PRA MLCC was only temporary (fig-
ure 1C). 
Analysis of anti-HLA antibody specificity 
by Luminex before and after IVIg
Every patient included in the study (except
control patient 8) had had one or more previous
transplantations. Consequently, we analysed more
precisely the specificities of HLA class I and class
II antibodies of each patients, focusing on the HLA
antigens expressed by previous grafts before IVIg
treatment, at the end of the monthly treatment and
a few months after the last IVIg infusion (figure 2).
Each anti-HLA specific antibody in figure 2 was
detected by LABScreen® PRA and confirmed by
LABScreen® Single Antigen. For HLA class I,
fluctuations of the specific anti-HLA antibodies
after the three IVIg infusions were observed in all
patients (figure 2A left). The fluctuations were
transient in patients 1 and 2. In patients 3 and 5,
we observed a small but persistent decrease in the
intensity of all specific anti-HLA class I anti-
bodies. In patient 4, a sustained increase of the
specific anti-HLA class I antibodies intensity was
recorded. These results contrast with the persist-
ent drop of PRA MLCC shown in figure 1. For
anti-HLA class II antibodies (figure 2A right), we
observed a transient reduction of specific anti-
HLA antibodies in patients 1 and 5, and an increase
of specific anti-HLA antibodies in patients 2 and
4. Patient 3 had a persistent absence of anti-HLA
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Figure 2
Changes in Donor Specific Antibodies (DSA) during the study determined by Luminex.
A For each patient, we focused our analysis on anti-HLA antibodies developed against HLA anti-
gens of a previous graft determined by LABScreen® PRA Class I (left column) and LABScreen®
PRA Class II (right column). The anti-HLA antibodies detected were confirmed by LABScreen®
Single Antigen (data not shown). The levels of anti-HLA antibodies with intensities of 6 and 8 are
calculated as the ratio between the mean fluorescence of each serum-HLA microbead and the
mean fluorescence of the positive control (LABScreen® PRA). Due to the high sensitivity of this
test, only intensities of 6 and 8 were taken into account. 
Anti-HLA antibodies were analysed before IVIg infusion at the end of the treatment (End TT) 
and 6 months after (distant). We also report the result of patient 4 after the first (End 1st TT) 
and second (End 2nd TT) IVIg infusion.
B In control patients, we analysed anti-HLA antibodies developed against HLA antigens of a previ-
ous graft over time (3 and 6 months). Anti-HLA antibodies developed against HLA antigens of a
previous graft determined by LABScreen® PRA Class I (left column) and LABScreen® PRA Class II
(right column). The anti-HLA antibodies detected were confirmed by LABScreen® Single Antigen
(data not shown). As control patient 8 had not received a prior graft, we analyzed the major anti-
HLA antibodies detected. Due to the high sensitivity of this test, only intensities of 6 and 8 were
taken into account. 
TT = treatment
Figure 2a
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Discussion
Our study showed that IVIg infusion at the
dosage of 1 g/kg was safe but induced a significant
reduction of the PRA MLCC in only one of our
five patients. Anti-HLA antibody levels, measured
with a highly sensitive technology, fluctuate natu-
rally over time, with or without IVIg treatment.
Therefore our data suggested that IVIg alone had
no direct effect on specific anti-HLA antibody
repertoire. 
These results in a small group of HS patients
are much less impressive than those reported in
previous studies, where a greater number of pa-
tients obtained a significant reduction of the PRA
[11–14] with IVIg at 2 g/kg [12, 13, 25], at 0.4 g/kg
or 0.1 g/kg in addition to plasmapheresis [11, 25,
28]. Although IVIg is generally used at 2 g/kg to
treat several autoimmune diseases, very few stud-
ies have been designed to compare IVIg dosages in
these disorders. Besides, IVIg at 1 g/kg has been
shown to be effective in ITP [29] and myasthenia
gravis [30]. Due to the price of IVIg treatment and
its side effects, some of which have been shown to
be dose related, it made sense to try to find the
most cost effective IVIg dosage for such therapy.
Our results suggested that 1 g/kg was not sufficient
to reduce the PRA MLCC in a significant number
of patients. The discrepancy in the results obtained
by other investigators can be due to the difference
in dosage and numbers of cure. However, it is dif-
ficult to compare these studies because some
groups infused IVIg in addition to plasmapheresis
or other immunosuppressive drugs and deter-
mined the effect by crossmatch with potential
donors [25]. Crossmatching remains the final test
before kidney transplantation, but as it is not
highly sensitive and dependent on anti-HLA cyto-
toxic antibody, it is of great interest to identify
precisely the anti-HLA antibody repertoire with 
a highly sensitive approach to decrease the risk of
humoral rejection after transplantation. The
Control 6
0 3 6
0
20
40
60
Class I (A3)
0
40
80
120
160
Class II (DR11)
Class II (DR7)
0 3 6
Control 7
0
60
120
180
240
Class I (A2)
0 3 6
0
80
160
240
320
400
Class II (DR53)
Class II (DR7)
0 3 6
Control 8
Class I (A2)
0 3 6
0
40
80
120
160
0
20
40
60
Class II (DR53)
Class II (DR1)
0 3 6
ssalCI ssalC II
Le
ve
l o
f A
n
ti-
H
LA
 a
n
tib
o
d
y
class II antibody (figure 2A right). To compare our
results with the control group, we assessed the
anti-HLA specific antibodies over time in the 3 HS
patients (table 1) who did not receive IVIg treat-
ment. In this group, we observed comparable fluc-
tuations of the anti-HLA antibodies intensity for
both HLA class I and class II specific antibodies
(figure 2B). 
Figure 2b
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highly specific and sensitive Luminex technology
is considered as an accurate approach for the de-
tection of anti-HLA antibodies [31]. We used this
technology to determine the repertoire of anti-
HLA antibodies in HS patients waiting for kidney
transplantation. The absence of any reduction in
PRA MLCC after IVIg infusion does not mean
that specific anti-HLA antibodies could not be tar-
geted by the IVIg treatment. Our data show that
the anti-HLA antibody repertoire analysed by Lu-
minex did not demonstrate any prolonged differ-
ence before and after IVIg treatment. Surprisingly
the HLA antibody repertoire in patient 4 whose
PRA levels determined by MLCC dropped signif-
icantly were not modified either. We can argue the
dose of IVIg were not sufficient to reduce the anti-
HLA antibodies detected at high level (intensity of
6 and 8). However, when we checked anti-HLA
antibodies present at a lower level (intensity of 4),
we did not observe any significant modification 
of the anti-HLA repertoire after IVIg treatment
either (data not shown). Wassmuth et al. strongly
suggest that the inhibitory effet of the IVIg on
HLA-alloantibody tested in vitro is related to in-
teraction with complement rather than anti-idio-
typic antibodies [32]. Our in vivo data tend to con-
firm the in vitro results found in this study [32].
The persistence of a high level of anti-HLA anti-
bodies after IVIg treatment without modification
of the repertoire is a strong argument against a di-
rect inhibition of the specific antibody production
by B cells and plasma cells, or the presence of anti-
idiotypic antibody able to block anti-HLA anti-
bodies.
A far as we know, the impact of anti-idiotypic
antibodies at the level of anti-HLA antibodies has
never been demonstrated. Commercially available
IVIg has been shown to contain anti-idiotypic an-
tibodies able to neutralise autoantibodies in se-
lected autoantibody-mediated autoimmune dis-
eases [33–36], and to down-regulate the synthesis
of antibodies by B cells that express the relevant
idiotype [18]. However, a recent report demon-
strated that IVIg preparations from multiparous
women have increased levels of anti-idiotypic 
antibodies specific for anti-HLA alloantibodies
which can significantly inhibit an established IgG
anti-HLA immune response in a humanised SCID
mouse model [37]. 
Our data suggest that at this dosage, IVIg
alone may not be sufficient to eliminate specific al-
loantibodies in HS patients. It might necessitate an
association with other immunosuppressive drugs,
as demonstrated by Zachary et al. who combined
low-dose IVIg (CMV-Ig), plasmapheresis and
quadruple sequential immunosuppression [25], or
an association with monoclonal antibody such as
anti-CD20 to achieve this objective [38, 39].
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